325 related articles for article (PubMed ID: 23581296)
1. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Sommer EM; Dry H; Cross D; Guichard S; Davies BR; Alessi DR
Biochem J; 2013 Jun; 452(3):499-508. PubMed ID: 23581296
[TBL] [Abstract][Full Text] [Related]
2. AKT-ing out: SGK kinases come to the fore.
Moniz LS; Vanhaesebroeck B
Biochem J; 2013 Jun; 452(3):e11-3. PubMed ID: 23725458
[TBL] [Abstract][Full Text] [Related]
3. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
García-Martínez JM; Alessi DR
Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
[TBL] [Abstract][Full Text] [Related]
4. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
5. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors.
Najafov A; Shpiro N; Alessi DR
Biochem J; 2012 Dec; 448(2):285-95. PubMed ID: 23030823
[TBL] [Abstract][Full Text] [Related]
6. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Bago R; Sommer E; Castel P; Crafter C; Bailey FP; Shpiro N; Baselga J; Cross D; Eyers PA; Alessi DR
EMBO J; 2016 Sep; 35(17):1902-22. PubMed ID: 27481935
[TBL] [Abstract][Full Text] [Related]
7. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3.
Murray JT; Campbell DG; Morrice N; Auld GC; Shpiro N; Marquez R; Peggie M; Bain J; Bloomberg GB; Grahammer F; Lang F; Wulff P; Kuhl D; Cohen P
Biochem J; 2004 Dec; 384(Pt 3):477-88. PubMed ID: 15461589
[TBL] [Abstract][Full Text] [Related]
8. PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X; Yu J; Yan J; Dai J; Si L; Chi Z; Sheng X; Cui C; Ma M; Tang H; Xu T; Yu H; Kong Y; Guo J
Cancer Biol Ther; 2018 Jul; 19(7):584-589. PubMed ID: 29708815
[TBL] [Abstract][Full Text] [Related]
9. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract][Full Text] [Related]
10. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase.
Kobayashi T; Deak M; Morrice N; Cohen P
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):189-97. PubMed ID: 10548550
[TBL] [Abstract][Full Text] [Related]
12. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a).
Brunet A; Park J; Tran H; Hu LS; Hemmings BA; Greenberg ME
Mol Cell Biol; 2001 Feb; 21(3):952-65. PubMed ID: 11154281
[TBL] [Abstract][Full Text] [Related]
14. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
16. Serum- and glucocorticoid-induced kinase drives hepatic insulin resistance by directly inhibiting AMP-activated protein kinase.
Zhou B; Zhang Y; Li S; Wu L; Fejes-Toth G; Naray-Fejes-Toth A; Soukas AA
Cell Rep; 2021 Oct; 37(1):109785. PubMed ID: 34610303
[TBL] [Abstract][Full Text] [Related]
17. The mechanical stress-activated serum-, glucocorticoid-regulated kinase 1 contributes to neointima formation in vein grafts.
Cheng J; Wang Y; Ma Y; Chan BT; Yang M; Liang A; Zhang L; Li H; Du J
Circ Res; 2010 Nov; 107(10):1265-74. PubMed ID: 20884880
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic MNK signalling regulates the metastasis suppressor NDRG1.
Tian S; Wang X; Proud CG
Oncotarget; 2017 Jul; 8(28):46121-46135. PubMed ID: 28545025
[TBL] [Abstract][Full Text] [Related]
19. In vivo role of the phosphate groove of PDK1 defined by knockin mutation.
Collins BJ; Deak M; Murray-Tait V; Storey KG; Alessi DR
J Cell Sci; 2005 Nov; 118(Pt 21):5023-34. PubMed ID: 16219676
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SGK1 enhances mAR-induced apoptosis in MCF-7 breast cancer cells.
Liu G; Honisch S; Liu G; Schmidt S; Pantelakos S; Alkahtani S; Toulany M; Lang F; Stournaras C
Cancer Biol Ther; 2015; 16(1):52-9. PubMed ID: 25427201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
